Sub-Q Bionics Raises $1.5M to Develop Implantable Lymphedema Device
Not every problem gets a spotlight. Lymphedema has been sitting in the corner for years, affecting millions with swelling, discomfort, and a daily grind of compression therapy that feels more like maintenance than medicine. The kind of space where real innovation does not announce itself, it earns its way in.
Sub-Q Bionics just stepped into that silence and turned up the volume with a $1.5M pre-seed round. Backed by Mayo Clinic, Yeda, a handful of private investors, and matching support from the Israel Innovation Authority, this is the kind of cap table that doesn’t chase noise, it studies it, dissects it, then funds the signal.
Jordan Pollack and David Knapp are not guessing their way through this. One brings the operator mindset shaped inside Boston Scientific and the startup trenches, the other carries deep R&D gravity from leading innovation at scale. Together, they are building something that sits under the skin and overdelivers where legacy care has stalled.
The play here is precise. An implantable lymphatic drainage system designed to move fluid, reduce swelling, and give patients something radical in healthcare. Consistency. Not another wearable. Not another routine to manage. Something embedded, working quietly, like good infrastructure should.
And let’s talk about that name for a second. Sub-Q Bionics. Subcutaneous by definition, but also subverting expectations. Because the real flex is not making more noise in medtech, it is making less friction for the patient. That is where the market shifts.
The Mayo Clinic licensing angle matters more than most will admit. This is not just capital, it is clinical proximity. It is access to surgical insight, validation pathways, and the kind of institutional knowledge that shortcuts years of wandering. Yeda brings the science backbone. Israel Innovation Authority brings strategic belief. That triangle is not accidental.
Early stage, yes. No revenue headlines, no inflated metrics, no victory laps. Just a focused team in Stillwater with ties into Minneapolis and Tel Aviv, building for a patient population that has been underserved for too long.
The takeaway is simple if you are paying attention. The best companies are not chasing crowded problems. They are going where the need is obvious but the solutions are not. They partner early, build with clinicians not around them, and raise just enough to prove the next truth. Sub-Q Bionics is not trying to be loud. They are trying to be effective. And in this market, that is the kind of signal worth following.
